Thymosin‐β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma
Belamy B. Cheung(Children's Cancer Institute Australia), Glenn M. Marshall(Children's Cancer Institute Australia)
Cited by 17
Related Papers
TRIM16 Acts as an E3 Ubiquitin Ligase and Can Heterodimerize with Other TRIM Family Members
|PLoS ONE|2012|115
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
|Nature Communications|2021|87
TRIM16 acts as a tumour suppressor by inhibitory effects on cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells
|Oncogene|2010|70